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Abstract
The consumption of herbal products and dietary supplements along with 
conventional medicines has raised concerns regarding herb-drug interactions. 
The available literature from experimental and clinical studies suggested that 
the consumption of herbs or dietary supplements that modulate efflux proteins, 
especially P-glycoprotein (P-gp) and metabolic enzyme CYP3A, may cause clini-
cally relevant herb-drug interactions by alteration of bioavailability and disposition 
profiles of targeted drug. It has been also hypothesized that both CYP3A and P-gp 
work synergistically to limit systemic exposure of orally administered substrate 
drugs. Many in vitro and in vivo studies suggested that co-administration of flavo-
noids significantly enhances the bioavailability of orally administered drugs, which 
may be due to inhibition of the CYP3A enzyme and P-gp transporter. Recently, a 
large number of orally administered tyrosine kinase inhibitors (TKIs) have been 
clinically approved for cancer chemotherapy, and many are currently estimated to 
be under development. TKIs are all primarily metabolized by CYP3A, and most of 
them are also substrates of P-gp. Numerous studies have suggested that the plasma 
exposure of orally administered TKIs increases when co-administered with other 
drugs due to their dual inhibitory activities against P-gp and CYP3A. However, 
limited data are available regarding the interaction between flavonoids and TKIs. 
The objective of this article is to review the potential role of flavonoids in modula-
tion of CYP3A enzyme and P-gp transporter and their influence on bioavailability 
and disposition of TKIs.
Keywords: flavonoids, tyrosine kinase inhibitors, CYP3A4, P-glycoprotein, 
bioavailability, disposition
1. Introduction
Due to common belief that natural medicines are much safer than synthetic one, 
the use of complementary and alternative medical therapies (CAMs) has become a 
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common trend around the world. It can be used either alone or in combination with 
prescription medicines [1]. According to an estimate of World Health Organization 
(WHO), approximately 80% of the developing countries’ population relies on 
CAMs for their primary healthcare needs [2, 3]. CAMs have been also become 
popular around the developed countries, and this has led to a tremendous growth 
in international herbal drug market for the last 15 years [4–6]. Consumption of 
CAMs is more pronounced in patients diagnosed with cancer or human immune 
virus (HIV) infection, especially with regard to various antidepressant and energy 
treatments to cope with their mental and physiological instability [7]. The bioavail-
ability and the distribution characteristics are the key factor for the therapeutic 
effects of pharmaceuticals at their site(s) of action in the tissue [8]. Due to higher 
consumption of CAMs (herbal extracts and dietary supplements) with prescription 
medicines, there is a growing awareness that herbal remedies and/or phytoconstitu-
ents may affect the bioavailability and disposition characteristics of conventional 
pharmaceuticals [9]. The medical and scientific literature supported by in vitro and 
in vivo laboratory studies including preclinical and clinical trials suggested that 
the co-administration of natural products or its phytoconstituents may affect the 
metabolism and bioavailability of prescription drugs, which significantly increasing 
the risk of serious (clinical) adverse reactions or therapeutic failure. The primary 
mechanisms underlying the herb-drug interactions involve either the induction 
or the inhibition of intestinal drug efflux pumps (including efflux proteins, such 
as P-gp and MRPs) and the intestinal and hepatic metabolism mediated by cyto-
chrome P450 enzymes (CYP3A) [10–12]. Hence, the consumption of herbs that can 
modulate efflux proteins and/or CYP3A may cause clinically relevant herb-drug 
interactions and alter drug bioavailability [13, 14]. Any inhibitory effect of herbal 
extracts/constituents on efflux proteins and/or CYP3A may result in high exposure 
of substrate drugs in plasma and tissue and lead to toxicity, whereas any inductive 
effect may cause low exposure, leading to a decrease in efficacy and treatment 
failure.
The biological effects produced by CAMs are due to the presence of various 
classes of phytochemicals present there, that is, alkaloids, flavonoids, terpenoids, 
carotenoids, polyketides, and phenylpropanoids. Among them, flavonoids have 
attracted much interest due to their numerous pharmacological activities and 
health benefit in the form of their antioxidant, anti-inflammatory, antimutagenic, 
antibacterial, antiangiogenic and enzyme modulatory, antiallergic, and anticancer 
activities [15, 16] and become the main components of herbal products where it 
presents in the form of quercetin, genistein, hypericin, kaempferol, and silibinin. 
There is accumulated evidence in the literature, which confirms that flavonoids 
modulate drug metabolism. Modulation may happen by either (1) altering the 
expression and/or activity of P450 enzymes, (2) affecting the P-gp-mediated cellu-
lar efflux of drugs, and/or (3) inhibiting the intestinal glucuronidation of the drug. 
This evidence confirms that the consumption of flavonoids or flavonoid-containing 
dietary supplements with conventional pharmacotherapeutic regimens should need 
to be examined to avoid drug-flavonoid interactions [17–21].
Among the novel classes of anticancer drug development, small molecule 
tyrosine kinase inhibitors (TKIs) currently represent one of the most promising 
and rapidly expanding groups. Almost 25 TKIs (mostly in oral dosage form) have 
been already approved by international drug agencies, >130 are being evaluated in 
different phases of clinical trials, and many more are in various stages of develop-
ment [22, 23]. Most of TKIs are primarily metabolized by CYP3A4 and also interact 
with P-gp and/or Breast Cancer Resistance Protein (BCRP) where it serves as both 
substrates and inhibitors. Considering the dual roles of TKIs on both CYP3A4 and 
drug transporters (P-gp, BCRP) and its influence in drug disposition, the potential 
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of TKI-drug interactions is an important consideration [24, 25]. In addition, most 
TKIs are being used orally and prescribed for long duration along with other 
medications, which may result in significant drug-drug interactions (DDI). This 
review provides a comprehensive overview of the potential role of flavonoids in 
modulation of CYP3A enzyme and P-gp transporter and their possible influence on 
bioavailability and disposition of tyrosine kinase inhibitors (Figure 1).
2. CYP3A
Cytochrome P450 enzymes (CYP) are the most versatile enzyme system 
involved in detoxification and oxidative metabolism of various endogenous sub-
strates (steroid hormones, lipids, and bile acids) and xenobiotics (drugs, environ-
mental pollutants, and dietary products) [26, 27]. It consists of over 400 isoforms, 
and their activities can be increased or decreased by many drugs either by inducing 
the biosynthesis or by directly inhibiting its activity, which is a major source for 
drug-induced toxicity via DDI. CYP3A enzymes, which constitute the predomi-
nant phase I drug-metabolizing enzymes, are estimated to metabolize between 50 
and 70% of currently administered drugs [28]. Alone CYP3A4, which is the most 
abundant congener of the CYP3A family contributes approximately 30% of hepatic 
CYP activity and more than 70% of intestinal CYP activity [29]. Many drugs used 
in different types of therapies are substrates for CYP3A4, and it is presented at high 
levels in both liver and intestine [30, 31]. Reports from in vitro and in vivo studies 
have already established that naturally occurring dietary supplements and phyto-
constituents can modulate hepatic and enterocytic CYP activity.
CYP inhibition-mediated DDI is widely recognized, and the necessity of the 
enzyme inhibition studies is included in the guidance from the USFDA [32]. 
Usually, two types of CYP inhibition occur: (1) reversible inhibition represented 
Figure 1. 
Schematic layout for prediction of flavonoids in modulation of CYP3A enzyme and P-gp transporter and its 
influence on disposition of TKIs.
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by competitive inhibition, which is concentration-dependent inhibition and  
(2) irreversible inhibition, also called mechanism-based inhibition (MBI), where 
during inhibition process enzyme is inactivated by stable complex formation with 
a metabolite. In MBI, enzyme reduction activity continues until the inactivated 
CYP is replaced by a newly synthesized CYP, the duration of the elevated blood 
concentration of a drug coadministered with a mechanism-based inhibitor is 
longer. Therefore, MBI requires more attention because they have been reported 
to cause unanticipated adverse effects [33, 34].
3. P-gp
P-gp is an adenosine triphosphatase (ATPase) energy-dependent, membrane-
bound protein that belongs to the ABC efflux transporter family [35]. The ABCB1 
gene, which is also known as the multidrug resistance 1 (MDR1), encodes P-gp and 
is responsible for cellular efflux of numerous drugs [36]. It is more prominent in 
various resistant human tumors, where it is believed to be the major factors respon-
sible for multidrug resistant (MDR). P-gp-mediated transport of drugs is saturable, 
ATP-dependent, osmotically sensitive mechanism that generates a concentration 
gradient. In intestines, P-gp expressed in apical side of the epithelial cells where 
it pumps the drug back into the GI lumen resulting in fecal excretion. In liver, it 
presents in canalicular surface of hepatocytes to remove drug and metabolites from 
the interior of the cell. In brain, it is expressed in endothelial cells of blood brain 
barrier and prevented the entry of xenobiotics into brain. In kidney, it is expressed 
in proximal tubes of kidney to efflux drug into urine and in certain hematological 
cells to put drug back into circulation [37–40]. Higher expression of P-gp in excre-
tory organs (liver and kidney) facilitates metabolism of substrate drugs via biliary 
excretion and renal elimination. As an efflux transporter, ABCB1 prevents intestinal 
absorption of orally administered drugs and limits its oral bioavailability. A broad 
range of clinically used drugs are substrate of P-gp, including anticancer agents 
(anthracyclines, vinca alkaloids, epipodophyllotoxins, methotrexate, and taxol) 
[41], cardiac drugs (digoxin and quinidine) [42], protease inhibitors (saquinavir, 
indinavir, and ritonavir) [43], immunosuppressants (cyclosporine) [44], and 
antibiotics (actinomycin D) [45].
4. Interplay between CYP3A and P-gp
Various preclinical and clinical studies have postulated that both CYP3A enzyme 
and P-gp transporter display strong effects in modulation of oral drug bioavail-
ability and elimination of numerous drugs. Both CYP3A and P-gp act in functional 
collaboration during the first-pass elimination of drug [46]. Extensive overlap 
exists between the substrate specificities and the tissue-specific expression patterns 
of P-gp and CYP3A, especially in the liver (hepatocytes) and intestine (enterocytes) 
[47, 48]. It has also been predicted that the orally administered drugs, which are 
dual substrates of P-gp and CYP3A, the back-transportation mechanism by P-gp in 
intestinal epithelial cells, are available for further CYP3A4-mediated metabolism 
within these cells resulting in massive first-pass effects in intestine [49]. The com-
bined action of these two pathways was expected to be more efficient than the sum 
of their individual activities, resulting in synergistic effects of P-gp and CYP3A.
Two mechanistic frameworks have been suggested to support the possible 
synergistic action of P-gp and CYP3A in intestine. Under the first mechanism, 
P-gp acts to decrease the level of intracellular concentration of a substrate drug in 
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enterocytes, thus preventing possible saturation of the CYP3A enzyme by main-
taining the drug within the linear range for metabolic activity. Under the second 
mechanism, the functional effects of P-gp, together with subsequent drug reup-
take, allow the repetition of drug substrate, and therefore, probability of the drug 
to be metabolized increases by prolonged access to enterocyte CYP3A. The above 
cyclic repetition of drugs per se would itself increase the drug metabolism, even 
without considering saturating or nonsaturating conditions for CYP3A [50]. Based 
on above evidence, it is concluded that induction and inhibition of (intestinal) P-gp 
and CYP3A4 are important mechanisms underlying DDIs [51].
The hypothesis of synergistic collaboration between CYP3A and P-gp was 
clarified in a study that showed a dramatic increase in the systemic exposure of 
docetaxel and the risk of intestinal toxicity in P-gp−/−CYP3A−/− double knock-
out mice. After oral administration of docetaxel, 3-fold and 12-fold increases 
in bioavailability were observed in P-gp−/− and CYP3A−/− mice, respectively, in 
comparison with wild-type mice. However, when both of the primary detoxifica-
tion systems were missing, that is, in P-gp−/−CYP3A−/− double knockout mice, 
bioavailability showed a disproportionate increase in >70-fold in comparison with 
wild-type mice [48].
Within the context described above, it is clear that drugs that are dual substrates 
for P-gp and CYP3A are highly susceptible to herb-drug interactions. Therefore, 
the consumption of herbs that modulate efflux transporters and CYP3A may cause 
clinically significant drug-herb interactions and alter drug bioavailability [13, 14]. 
The inhibitory effect of herbs on P-gp and CYP3A may result in increasing the 
drug concentration level in the plasma and tissues, leading to toxicity, whereas any 
inductive effect may result in lowering the concentration level, leading to loss of 
efficacy and/or treatment failure (Figure 2).
5. Regulation of CYP3A and P-gp expression
Pregnane X receptor (PXR) is a highly promiscuous nuclear hormone receptor, 
generally expressed on sites that are important to drug dispositions (e.g., small 
intestine, liver, and kidney). The human orthologue of PXR is also known as steroid 
Figure 2. 
Potential functional relationships between P-gp and CYP3A4 in enterocytes.
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and xenobiotics receptor (SXR) and is coded by NR 112. It has been reported that 
PXR regulates the expression of CYP3A and several other genes encoding protein 
and other enzymes, which involves in drug disposition including P-gp [52, 53]. 
Based on this evidence, Maglich et al. hypothesized that PXR plays a more impor-
tant role in the regulation of drug metabolizing enzymes and drug transporters in 
the small intestines [54]. The observation that PXR regulates both CYP3A and P-gp 
provides further evidence for the argument that these proteins coordinately medi-
ate detoxification of many xenobiotics during oral absorptions [46]. Synold et al. 
were the first to describe coregulation of drug metabolism and efflux via CYP3A 
and P-gp in liver and intestine by the human receptor PXR/SXR. Their results 
indicate that paclitaxel reduces its own oral bioavailability by activating the PXR 
and induces its own metabolism and biliary elimination [55].
6. Experimental models for P-gp and CYP3A-mediated DDI studies
6.1 In vitro model for CYP3A and P-gp studies
The in vitro CYP inhibition study is usually performed in human liver 
microsomes (HLMs) or human liver hepatocytes (HLHs), Caco-2 cell lines, or 
recombinant CYP (rCYP) enzymes [56]. The technology used for CYP inhibition 
includes luminescence, florescence, radiometric, and HPLC or LC-MS/MS assay. In 
florescence and luminescence assays, the metabolism of profluorescent or prolumi-
nescent substrate by CYP enzyme to give their fluorescent or luminescent product, 
respectively, is measured in rCYP enzyme. In radiometric method, the release of 
radiolabel on metabolism of substrate is measured in HLM. In HPLC or LC-MS/MS 
assay, the concentration of substrate/probe drugs is measured in HLM, HLH, and 
rCYP enzymes [57].
The in vitro analyses used for P-gp-mediated efflux studies include cytotoxicity 
assay, accumulation/efflux assays, transport assays, and ATPase assays. In cytotox-
icity assays, the IC50 end point (concentration of P-gp substrates or inhibitors) that 
inhibits the growth of P-gp expressing cells is measured. In accumulation/efflux 
assay, the accumulation of drugs in P-gp expressing cells is measured. In transport 
assays, the permeation of drugs from apical-to-basolateral and basolateral-to-apical 
compartment in polarized epithelial cells is measured, whereas in ATPase assay, the 
stimulation or inhibition of P-gp ATPase enzyme activity in membranes of P-gp 
expressed cells is measured [58, 59].
6.2 In vivo models for CYP3A and P-gp-mediated DDI studies
Various strains of mice (including transgenic and knockout), rats, and nonhu-
man primate (monkey) have been used for CYP3A, P-gp, and dual CYP3A/P-gp-
mediated DDI studies [60].
Since midazolam and triazolam are specifically extensively metabolized by 
CYP3A4 and ketoconazole is a potent inhibitor of CYP3A4, several groups of studies 
used as model for experimental CYP3A-mediated DDI studies. Moreover, mid-
azolam is not a substrate for P-gp, whereas the ketoconazole can effectively inhibit 
both CYP3A and P-gp, which can confirm that the interaction between them can 
be sole attributed to effects on CYP3A. CYP gene knockout and humanized mice 
have been established for CYP3A-mediated drug interaction using midazolam as 
substrate [61]. Several strains of rats are most commonly used for CYP3A-mediated 
drug interaction using midazolam, diltiazem, nifedipine, and doxorubicin as 
substrates [62, 63]. In addition, cynomolgus monkey was also used as model for 
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CYP3A-mediated DDIs; however, its choice is limited due to its high cost, handling, 
and ethical concerns [64].
Valspodar, elacridar, and zosuquidar are more selective P-gp inhibitors and 
thought to be low affinity for CYP enzymes, and other drug transporter proteins are 
commonly used for in vivo DDI studies in mice and rats. The drugs such as pacli-
taxel, cyclosporine, and digoxin are most commonly used as substrates for P-gp-
mediated inhibition. Moreover, Rho123 is attractive probe and has been widely used 
as marker to evaluate P-gp functions because it is not a substrate for CYP3A enzyme 
[65–67]. The cynomolgus monkey has been also used as model to evaluate effect of 
P-gp-mediated DDI using erythromycin and fexofenadine as substrate [64, 68].
The evaluation of flavonoid-mediated DDI by using dual substrates of CYP3A 
and P-gp, inhibitors, and species has been discussed in detail in Section 9 and sum-
marized in Table 1.
7. Flavonoids as P-gp and CYP3A modulators
Flavonoids (a group of polyphenolic compounds) are mainly abundant in 
vegetables and fruits and routinely consume through our common diet and in the 
form of beverages (plant-derived), for example, wine and tea [37]. In addition, they 
are the main constituents of many herbal products/formulations. Structurally, these 
compounds possess a framework consisting of a chromane ring together with an 
aromatic ring that is attached at different positions. Based on various substitutions 
and the oxidation status of the ring C atoms, flavonoids can be categorized into 
various subclasses, including flavones, flavonols, flavonones, flavanols, isoflavones, 
and chalcones. Since the last decade, there has been a drastically increase in scien-
tific work on flavonoids, with >2000 publications/year containing “flavonoids” 
as a keyword found in different literature sources. Flavonoids display antioxidant, 
anticarcinogenic, antiviral, anti-inflammatory, and antiesterogenic properties, and 
high intake of flavonoids has been linked with a reduced risk of cancer, cardiovas-
cular disease, osteoporosis, and other age-related degenerative diseases [37, 69].
Due to the wide range of health benefits of flavonoids and their remarkable 
safety record, numerous herbal preparations containing these compounds are 
marketed in various formulations as dietary supplements. The total daily intake 
of flavonoids in the average US diet has been estimated to be more than 1 g [37]. 
Therefore, the concentration of flavonoid expected to be present is sufficient after 
the ingestion of flavonoids and/or flavonoid-containing supplements, suggesting a 
potential herb-drug interaction.
Thus, the consumption of higher doses of flavonoids is common in daily life, 
and it may increase the risk of pharmacokinetic interactions with clinically used 
Flavonoids Dose-dependent (IC50) 
inhibition of CYP3A4 activity
↑ Cellular accumulation of 
rhodamine (MCF-7/ADR cell)
References
Quercetin 1.97 μM 3–10 μM [83]
Myricetin 7.8 μM 10–30 μM [84]
Baicalein 9.2 μM 1–10 μM [85]
Baicalein 9.2 mM 10–30 μM [86]
Silibinin 1.8 μM — [87]
Table 1. 
In vitro effects of some common flavonoids on CYP3A4 and P-gp activity.
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medicine. This concern is also confirmed by increasing evidence, which showed 
significant or even life-threatening interactions between flavonoids or flavonoid 
containing products and prescription drugs [70, 71].
Initial publications cite various examples of flavonoids as P-gp transport 
inhibitors, thereby affecting the bioavailability and cellular uptake of anticancer 
drugs. These experiments include in vitro analyses of the effects of flavonoids 
on the intracellular accumulation of P-gp substrates using P-gp-overexpressing 
cells and a variety of clinical and animal model studies, especially involving P-gp 
knockout animals [37]. For example, concomitant administration of quercetin 
increased moxidectin oral bioavailability in lambs [72]; oral bioavailability of 
quinine was increased by naringin [73]; cyclosporine by baicalein and its agly-
cone [74]; and paclitaxel by flavones in rats [75]. Similarly, quercetin increased 
the oral bioavailability of paclitaxel and tamoxifen in rats [76, 77] and digoxin 
in pigs, which results in high toxicity [78]. All of these studies indicate that 
flavonoid-P-gp interactions can occur in vivo, resulting in pharmacokinetic 
interactions. In contrast to the above results, several flavonoids appear to induce 
P-gp transport, resulting in a decrease in the bioavailability of substrate drugs. 
For instance, in vitro studies, kaempferol and quercetin, produced inductive 
effects on P-gp efflux [79, 80], and therefore, the consumption of pure herbal 
constituents, which contains hypericin, kaempferol, quercetin, and silibinin 
for 10 days, may produce a significant increase in the expression of P-gp mRNA 
[81]. In vivo studies have also indicated that long-term exposure (14 days) to St. 
John’s wort (a flavonoid-containing herbal product) leads to higher expression 
of MDR1 in the rat intestine [82]. Based on these findings, it has been concluded 
that chronic exposure to some flavonoids induces intestinal expression of P-gp, 
resulting in reduced intestinal drug absorption, possibly due to enhanced drug 
efflux; however, the inhibitory effects on P-gp-mediated efflux are based on 
short-term exposure. Meanwhile, subsequent in vitro and in vivo studies indicate 
that the pharmacokinetic interactions of drugs with flavonoids may result in 
the modulation not only of drug transporters (P-gp) but also of metabolizing 
enzymes, especially CYP3A, that is, dual inhibition of P-gp and CYP 3A. In vitro 
studies confirmed that quercetin, myricetin, baicalein, and silibinin were found 
to produce dose-dependent inhibition of CYP 3A4 activity in CYP inhibition 
assay and increased the cellular accumulation of rhodamine (MCF-7/ADR cell) 
in P-gp transport studies [83–87]. However, in another study, quercetin and 
rutin were found to induce the function of CYP 3A4 and P-gp, which may lead 
to increase the bioavailability of substrate drugs [88]. In vitro effects of some 
common flavonoids on CYP3A4 and P-gp activity are summarized in Table 1. 
In in vivo studies, coadministration of quercetin, baicalein, silibinin, epigal-
locatechein, and kaempeferol increased the bioavailability of oral tamoxifen dose 
dependently through inhibition of P-gp efflux and reduction in the first-pass 
metabolism through inhibition of CYP3A metabolism in the small intestine 
and/or liver [78, 84, 89–91]. Similarly, quercetin, silibinin, naringin, flavone 
(2-phenyl-4H-1-benzopyran-4-one), genistein, and morin also increased the 
oral bioavailability of paclitaxel mainly through inhibition of CYP3A4-mediated 
metabolism in the small intestine and/or liver and inhibition of the P-gp efflux 
in the small intestine [75–77, 92–94]. Additionally, quercetin, myricetin, and 
baicalein also reduced the bioavailability of doxorubicin by similar mechanism 
[83, 84, 95]. Similar results were also produced by morin, quercetin, and niringin 
with diltiazem and baicalein with nimodipine [85, 96–98]. In contrast, reduced 
oral bioavailability of tamoxifen by biochanin A and cyclosporine by quercetin 
and rutin was also reported in rats [88, 99]. In vivo interaction of flavonoids with 
dual substrates of CYP3A4 and P-gp is summarized in Table 2.
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Flavonoids  
(oral dose)
Dual substrate 
of CYP3A and 
P-gp  
(oral dose)
Aimals/
species
Effect on bioavailability parameters References
% change 
in Cmax
% change 
in AUC
Change in 
RBA* (fold)
Quercetin (2.5 
and 7.5 mg/kg)
Tamoxifen 
(10 mg/kg)
Rat ↑23–35 ↑ 34–60 ↑1.35–1.61 [78]
Baicalein  
(0.5, 3, and 
10 mg/kg)
Tamoxifen 
(10 mg/kg)
Rat ↑ 54.8–100 ↑47.6–89.1 ↑1.47–1.89 [86]
Silibinin (0.5, 2.5, 
and 10 mg/kg)
Tamoxifen 
(10 mg/kg)
Rat ↑45.2–78.6 ↑40.2–71.3 ↑1.40–1.72 [87]
Epigallocatechein 
(0.5, 3, and 
10 mg/kg)
Tamoxifen 
(10 mg/kg)
Rat ↑57.1–89.7 ↑48.4–77.0 ↑1.48–1.77 [90]
Kaempeferol (2.5 
and 10 mg/kg)
Tamoxifen 
(10 mg/kg)
Rat ↑48.9–47.7 ↑39.8–47.7 ↑1.40–1.48 [91]
Biochanin A 
(100 mg/kg)
Tamoxifen 
(10 mg/kg)
Rat ↓23.5 ↓32.3 ↓ 1.32 [99]
Quercetin  
(2–20 mg/kg, 
p.o.)
Paclitaxel 
(40 mg/kg)
Rat — — ↑ 1.76–3.29 [76]
Silibinin (0.5, 2.5, 
and 10 mg/kg)
Paclitaxel 
(40 mg/kg)
Rat ↑31.0–52.9 ↑65.8–
101.7
↑1.15–2.02 [87]
Naringin (1, 3, 10, 
and 20 mg/kg)
Paclitaxel 
(40 mg/kg)
Rat — — ↑1.35–1.69 [92]
Flavone 
(2–20 mg/kg)**
Paclitaxel** 
(40 mg/kg)
Rat — — ↑2.4–3.1 [75]
Genistein (3.3 
and 10 mg/kg)
Paclitaxel 
(30 mg/kg)
Rat — — ↑1.26–1.55 [93]
Morin 
(3.3–10 mg/kg)
Paclitaxel 
(30 mg/kg)
Rat ↑ 70–90 ↑30–70 ↑1.32–1.68 [95]
Quercetin (0.6, 3, 
and 15 mg/kg)
Doxorubicin 
(50 mg/kg)
Rat ↑ 35.1–125.7 ↑ 31.2–136 ↑1.33–2.36 [83]
Myricetin(0.4, 2, 
and 10 mg/kg)
Doxorubicin 
(40 mg/kg)
Rat ↑45–105 ↑51–117 — [84]
Baicalein (0.3, 
1.5, and 6 mg/kg)
Doxorubicin 
(40 mg/kg)
Rat — — ↑1.20–1.96 [95]
Morin (1.5, 7.5, 
and 15 mg/kg)
Diltiazem 
(15 mg/kg)
Rat ↑ 30–120 — 1.38–1.80 [96]
Quercetin (2, 10, 
and 20 mg/kg)
Diltiazem 
(15 mg/kg)
Rabbit — — 1.75–2.76 [97]
Naringin (5 and 
15 mg/kg)
Diltiazem 
(15 mg/kg)
Rat — — ↑2.07–2.20 [98]
Quercetin Cyclosporine Rat ↓67.8 ↓43.3 — [88]
Rutin Cyclosporine Rat ↓63.2 ↓57.2 — [88]
Baicalein (0.4, 2, 
and 8 mg/kg)
Nimodipine 
(12 mg/kg)
Rat — — ↑1.39–1.58 [85]
*RBA, relative bioavailability.
**Flavone, 2-phenyl-4H-1-benzopyran-4-one.
Table 2. 
In vivo interaction of some common flavonoids with dual substrates of CYP3A and P-gp.
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8. Significance of flavonoids as P-gp and CYP3A inhibitors
Various experimental and clinical studies confirmed that flavonoids produce 
antioxidant, anti-inflammatory, and anticarcinogenic effects. Studies also con-
firmed that these effects were attributed due to their inhibitions of efflux trans-
porter enzyme (P-gp) and/or drug metabolizing enzyme (CYP3A). Therefore, 
flavonoids as P-gp inhibitor may use with other chemotherapeutic drugs for cancer 
treatment [100]. Occurrence of P-gp protein in various body tissues affects the 
absorption, distribution, metabolism, and excretion of drugs. Therefore, the dual 
effect of anticarcinogenic and P-gp modulation may synergistically act for the 
treatment of cancer [101]. The chemotherapeutic treatment of metastatic brain 
tumors is limited due to its low distribution in brain tissue by blood brain barrier 
and blood-cerebrospinal fluid barrier. P-gp is presented in the apical membranes of 
these cells, and flavonoids can improve the permeation of chemotherapeutic drugs 
by inhibiting the P-gp-mediated efflux [102]. Flavonoids can be used as nontoxic 
P-gp and/or CYP3A inhibitors and by its coadministration could improve the bio-
availability of poorly unavailable drugs, especially for anticancer drugs, by interfer-
ing its clearance or inhibiting its metabolism [103]. P-gp presents in bile canaliculi 
and kidney suggested that it can also play a role in biliary and renal elimination of 
drugs. Coadministration of flavonoids (as P-gp inhibitors) can reduce the clear-
ance of anticancer drugs, for example, vinblastine, doxorubicin, and irinotecan 
[104, 105]. Flavonoids can also play an important role in reversal of MDR in cancer 
chemotherapy. P-gp-associated MDR is a serious concern for limitation of cancer 
treatment. P-gp occurrence in tumor cell has been extensively characterized, and its 
overexpression has been confirmed during relapse. Therefore, it can be concluding 
that P-gp inhibitors (flavonoids) can potentially reverse the MDR during cancer 
chemotherapy [106].
9. Tyrosine kinase inhibitors
The evidence of protein tyrosine kinase enzyme involvement in tumor develop-
ment makes it novel targets for selective chemotherapy and thus target for rational 
design of drug development. Now protein kinases, especially tyrosine kinases, are 
being used as main targets for drug development related to malignancy, resulting in 
the high approval rate of various TKIs by the FDA [24, 107]. Imatinib was the first 
of its kind, which was introduced clinically, followed by various molecules such as 
gefitinib, erlotinib, sorafenib, afatinib, nilotinib, bosutinib, crizotinib, ponatinib, 
lapatinib, sunitinib, and dasatinib, and many more are in pipeline [108]. Although 
mechanism of action of these compounds is same, that is, competitive ATP inhibi-
tion at the catalytic binding site of tyrosine kinases, they differ from each other in 
the spectrum of targeted kinase activity, pharmacokinetic profile, and compound-
specific adverse effects [109]. These TKIs have been developed in oral formulations, 
are administered on a daily basis, and usually prescribed at a fixed dose. Although 
oral administration may be convenient for patients as it can reduce health care costs, 
improve quality of life of patients, and avoid heavy burden of day-stay infusion 
units, this practice also displays a disadvantage, in that the oral bioavailability of 
most of TKIs is highly dependent on their absorption through gastrointestinal tract 
and first-pass hepatic metabolism [25, 107].
Almost all TKIs are rapidly absorbed, and their maximum plasma concentration 
(Cmax) was achieved in 3–6 h after oral administration except sunitinib (6–12 h). 
Food intake has no significant effect on the absorption of imatinib, dasatinib, 
gefitinib, sorafenib, or sunitinib. However, the bioavailability of lapatinib and 
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nilotinib is increased pronouncedly with food intake. Almost all TKIs are high to 
plasma protein (>90%) and therefore extensively distribute into tissues resulting 
in large volume of distribution and prolong terminal half-life. Excretion of TKIs is 
predominantly through feces, and only a small fraction is eliminated with urine. 
Almost all TKIs are dual substrates of CYP3A4 (the most abundant CYP in the 
human liver and intestine) and P-gp efflux transporter, except sorafenib, vande-
tanib, bosutinib, ibrutinib, cabozantinib, regorafenib, and ruxolitinib, which are 
only substrate of CYP3A4, whereas vemurafenib and afatinib, which are effluxed 
by P-gp only [24, 108, 110–121]. Table 3 summarizes the substrate potential of TKIs 
with CYP3A4 and/or P-gp.
10. Drug-drug interaction with TKI
DDIs represent a serious concern, especially for agents that influenced by 
efflux transporters and CYP3A4 enzyme, and can produce clinically relevant 
drug interactions by alteration of its bioavailability. Because the majority of TKIs 
TKIS CYP 3A4 P-gp References
Imatinib √ √ [108, 110, 111]
Gefitinib √ √ [24, 108, 115, 118]
Erlotinib √ √ [24, 118]
Sorafenib √ X [24, 108, 118]
Dasatinib √ √ [24, 108, 118]
Sunitinib √ √ [24, 108, 118]
Lapatinib √ √ [24, 108, 118]
Nilotinib √ √ [24, 108]
Crizotinib √ √ [108, 111, 118]
Vandetanib √ X [108, 111]
Vemurafenib X √ [108, 112, 118]
Axitinib √ √ [108, 111, 118]
Bosutinib √ X [108, 111, 118]
Pazopanib √ √ [108, 111, 118]
Ponatinib √ √ [108, 111, 118]
Dabrafenib √ √ [108, 111, 118]
Cediranib √ √ [114, 118]
Tandutinib NA √ [118]
Ibrutinib √ X [116, 121]
Afatinib X √ [108, 111]
Cabozantinib √ X [108, 111]
Regorafenib √ X [108, 111]
Ruxolitinib √ X [108, 117]
Osimertinib √ √ [120]
Table 3. 
Substrate potential of TKIs with CYP3A4 and/or P-gp.
Bioactive Compounds
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are substrate of CYP3A4 and/or P-gp, DDI with CYP3A4 and/or P-gp inhibitors 
and inducers must be taken into account, and they must be used with caution, as 
advised in the package insert. Recently, it has been reported that coprescription 
of those medicines, which may induce or inhibit the metabolic pathways used by 
TKIs, is very high. Overall coprescribing rates of drugs that induce metabolism 
of TKI and may lead to decrease the effectiveness of TKIs ranged from 23 to 57%, 
whereas coprescribing rates of drugs that inhibit metabolism of TKIs and may 
increase its toxicity ranged from 24 to 74% [122]. For example, coadministra-
tion of imatinib with dual inhibitors CYP3A4 and P-gp increases not only the 
plasma concentration but also the intracellular concentration of imatinib. Dual 
inhibitors CYP3A4 and P-gp, such as verapamil fluconazole, itraconazole [123], 
erythromycin, clarithromycin [124], cyclosporine [125], and ketoconazole 
[126], increased the intracellular concentration of imatinib by inhibiting both its 
CYP3A4-mediated metabolism and its efflux through P-gp, which might result 
in increasing its cellular toxicity. Moreover, P-gp-mediated efflux inhibition 
by proton pump inhibitors, such as pantoprazole, has reported to increase the 
brain concentration of imatinib [127]. In contrast, coadministration of CYP3A4 
inducers, such as rifampicin or certain antiepileptics, may lead to a reduction in 
imatinib exposure of up to 74% [24, 110]. Similarly, inhibitors of both CYP3A4 
and P-gp increase both the plasma and intracellular concentrations of dasatinib 
as well, which are also expected to occur for verapamil, erythromycin, clarithro-
mycin, fluconazole, itraconazole [123], cyclosporine [125], and ketoconazole 
[123, 128]. Concomitant administration of the CYP3A4 inducer rifampicin leads 
to a reduction in dasatinib exposure of 80% [24, 129, 130]. The area under curve 
(AUC) of nilotinib is increased 3-fold in healthy subjects receiving ketoconazole 
[130], whereas coadministration of CYP3A4 inducers, such as rifampicin, leads to 
a 4.8-fold reduction in nilotinib exposure [24, 129, 130]. Administration of gefi-
tinib in the presence of rifampicin reduces the AUC of gefitinib by 83%, while in 
the presence of itraconazole, the AUC of gefitinib is increased by 78% [24, 131]. 
Furthermore, coadministration of ketoconazole results in a 3.6-fold increase in 
lapatinib plasma exposure, whereas coadministration of carbamazepine results in 
a decrease in the AUC of lapatinib by 72% [24, 132]. Although the result of above 
studies confirmed the risk of frequent DDIs among TKIs, but did not addressed 
the clinical consequences of these, that is, increased toxicity or therapeutic 
failure. Moreover, in some cases, in spite of knowing, these potential interacting 
combinations could have been intentionally prescribed by physicians because 
they considered the potential benefits to outweigh the risks or because the patient 
had the ability to tolerate these combinations in the past [133]. Since most of 
these TKIs are relatively new, their scientific evidence that supports their DDIs 
is limited. Therefore, it is not unexpected to observe that medical oncologists are 
not able to report TKI DDI pairs, which might have a high probability of causing 
deleterious effects in the treatment of cancer patients [134].
11. Flavonoids and TKI interaction
Compounds that are capable of inhibiting the activity of tyrosine kinase 
receptors (RTKs) are expected to display antiproliferative properties. Various in 
vitro and in vivo studies suggested that most of the flavonoids quercetin, genistein, 
hesperidin, and naringenin have TKI properties, which play a significant role in 
its anticancer effects [135–138]. Due to antiproliferative properties, flavonoids can 
be use along with conventional TKIs in clinical practice and therefore it definitely 
raise concern of pharmacokinetic interaction. So, it is understood that similar to 
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conventional medicines, flavonoids act as dual modulators of CYP3A4 and P-gp, 
which may produce significant effects on the disposition kinetics of TKIs. In spite 
of that, limited data are available relevant to interaction of flavonoids with TKIs 
in the literature. St. John’s wort that contains numerous flavonoids was found 
to increase imatinib clearance by 43% and decrease its AUC and Cmax by 30 and 
29%, respectively [139, 140] in human subjects. Similarly, St. John’s wort may 
also decrease the plasma concentration of dasatinib, and its use is discouraged in 
patients receiving it [141]. Genistein (isoflavone) when administered for 15 days 
significantly decreased the Cmax and AUC of imatinib, whereas its single dose 
did not produce any effects in rats [142]. Silybin, a constituent of silymarin, also 
decreased the AUC of imatinib after multiple dose administration (15 days) in 
rats [143]. However, apigenin in single dose increased the AUC of imatinib but 
decreased it in multiple dose administration (15 days) in rats [144], which sug-
gests that apigenin may act as enzyme inhibitor in single dose and become inducer 
after long-term administration. Epigallocatechin-3-gallate also decreased the Cmax 
and AUC of sunitinib after single dose administration in rats [145]. However, Bas 
100, a novel mechanism-based CYP3A4 inhibitor, isolated from grapefruit juice 
increased 2.1-fold AUC of erlotinib after single dose administration [146]. Similar 
Flavonoids/constituents TKI 
inhibitors
Model Pharmacokinetic 
effects
References
St. John’s wort (300 mg, p.o) Imatinib 
(400 mg, 
p.o.)
Healthy 
volunteers
↓AUC (30%)
↑ Oral clearance 
(43%)
[139]
St. John’s wort (300 mg, p.o) Imatinib 
(400 mg, 
p.o.)
Healthy 
volunteers
↓AUC (30%)
↓ Cmax (29%)
[140]
Genistein (50, 100 mg/kg, p.o.) 
for 15 days
Imatinib 
(30 mg/kg, 
p.o.)
Rat ↓AUC (27–28%)
↓ Cmax (23–25%)
[142]
Genistein (50, 100 mg/kg, p.o.) 
single dose
Imatinib 
(30 mg/kg, 
p.o.)
Rat No effects [142]
Apigenin (165 mg/kg, p.o) for 
15 days
Imatinib 
(30 mg/kg, 
p.o.)
Rat ↓AUC (25%) [144]
Apigenin (165 and 252 mg/kg, 
p.o) single dose
Imatinib 
(30 mg/kg, 
p.o.)
Rat ↑ AUC (25–40%) [144]
Silybin (50 mg/kg, single and 
multiple for 15 days, p.o.
Imatinib 
(p.o.)
Rat ↓ AUC significantly [143]
BAS 100 (10 mg /kg, p.o.) Erlotinib 
10 mg /kg, 
p.o.)
Mice ↑ AUC (2.1 fold) [146]
Epigallocatechin-3-gallate 
(100 mg /kg, p.o.)
Sunitinib 
(30 mg/kg, 
p.o.)
Rats ↓Cmax (47.7%) 
↓AUC (51.5%)
[145]
Grapefruit juice (240 mL), p.o Nilotinib 
(400 mg, 
p.o.)
Healthy 
volunteers
↑ AUC (29%)
↑ Cmax (60%)
[147]
Table 4. 
In vivo pharmacokinetic interaction of flavonoids or flavonoids containing herbal constituents with TKIs.
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effects were produced by the intake of 240 ml of grapefruit juice (an inhibitor of 
CYP3A4 and P-gp), which are shown to increase the nilotinib AUC by 60%, and 
thus, coadministration of nilotinib with grapefruit juice is not recommended 
[147]. Additionally, a case study showed that patients who had already developed 
resistance to gefitinib treatment become responsive after the withdrawal of all 
CAMs [148]. Table 4 summarizes the pharmacokinetic interaction of flavonoids or 
flavonoids containing herbal constituents with TKIs in both experimental animals 
and clinical studies.
12. Conclusions
The CYP3A enzyme accounts approximately 30% of hepatic and more than 70% 
of intestinal CYP activity. P-gp efflux protein is encoded by ABCB1 gene (MDR1) 
and is responsible for cellular efflux of numerous drugs. PXR regulates both CYP3A 
and P-gp and coordinately mediates detoxification of many xenobiotics during oral 
absorptions. The flavonoid constituent-mediated modulation of CYP3A and P-gp 
is the main mechanism through which the bioavailability and disposition of con-
ventional drugs are regulated. The synergistically modulation of CYP3A and P-gp 
by flavonoids may increase the potency of chemotherapeutic drugs. Moreover, it 
increases the permeability of drugs in brain and reduces the MDR in cancer che-
motherapy. Most of the TKIs are oral dosage formulations and also dual substrates 
of CYP3A and P-gp, so the risk of pharmacokinetic interactions with flavonoids is 
expected on concurrent administration. Therefore, there is a compelling need to 
study the cellular and molecular mechanisms involved in the flavonoid-mediated 
modulation of CYP3A and P-gp and their expected impact on the exposure and 
disposition of TKIs. Results from some experimental and clinical studies have 
confirmed the interaction between TKIs and flavonoids, but these unwanted clini-
cal consequences in cancer patients have not been elaborated. However, even small 
changes in drug metabolism and pharmacokinetics of TKIs may lead to therapeutic 
failure or toxicity in cancer patients. Nevertheless, it is a challenging task to deter-
mine the clinical effects of the DDI due to the large interpatient variability in the 
pharmacokinetics of the TKIs.
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